Sunday, August 16, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
ENERGYArmy Corps Permits Line 5 Tunnel—Michigan Blocks PathtodayCRYPTOT. Rowe Price's Active Multi-Token Crypto ETF Is a Fee-War Warning Shot for Bitwise and Grayscale4 weeks agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer EarningstodayENERGYMichigan Renews Enbridge's Line 5 Tunnel Permit, Removing the Biggest Regulatory Overhang on the Stock4 weeks agoCRYPTOSEC Delays Crypto Rules—Uncertainty PersistsyesterdayTECHBosch's $225M CHIPS Award for Silicon Carbide Puts Wolfspeed and Onsemi on Notice4 weeks agoTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff RefundyesterdayENERGYNew Mexico Blocks Oracle's Data Center Gas Pipeline, Exposing the Fragility of Big Tech's Power Build-Out4 weeks agoTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. MakersyesterdayDEFENSEPentagon's Laser Weapon Contracts for Drone Defense Open a New Revenue Line for Northrop and L3Harris4 weeks agoHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis Wins2 days agoENERGYMichigan's Line 5 Permit Renewal Is a Clear Win for Enbridge — and a Setback for Pipeline Opponents4 weeks agoDEFENSEBlackSky Lands Multi-Year Satellite Contract2 days agoCRYPTOT. Rowe Price's Active Multi-Token Crypto ETF Is a Fee Story — and a Pressure Test for Bitwise and Grayscale4 weeks agoTECHFCC Eases Broadband Label Rules—ISPs Win Flexibility3 days agoHEALTHCARE & FDACMS's Site-Neutral and 340B Cuts Would Squeeze Hospital Systems and Hand Wins to Outpatient Rivals4 weeks agoDEFENSEIonQ Lands $28M U.S. Defense Quantum Contract3 days agoWHITE HOUSEWhite House Cybersecurity Clearinghouse Creates a Direct Revenue Line for CrowdStrike, Palantir, and Microsoft4 weeks agoHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock4 days agoWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes the Pecking Order — Microsoft and Oracle Gain, Open-Source Loses4 weeks agoENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask4 days agoHEALTHCARE & FDACMS's Site-Neutral and 340B Reform Proposal Squeezes Hospital Margins and Lifts Independent Pharmacies4 weeks agoHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance4 days agoDEFENSEU.S.-Iran Escalation and a Stalled Strait of Hormuz Are a Windfall for Tanker Owners and Defense Primes4 weeks agoWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing4 days agoENERGYNew Mexico's Pipeline Denial Puts Oracle's Data Center Expansion on Ice — and Highlights Every Hyperscaler's Power Risk4 weeks agoWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shift5 days agoTECHBosch's $225M CHIPS Award for Silicon Carbide Chips Is a Direct Threat to Wolfspeed's U.S. Market Share4 weeks agoDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gains6 days agoWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes Who Wins the Model Race4 weeks agoWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertainty6 days agoWHITE HOUSETrump's Defense Supply Chain Order Tightens Waiver Rules — Domestic Parts Makers Win, Foreign-Sourced Primes Face Friction4 weeks agoTECHTrump Administration Adds 6 Chipmakers to U.S. Portfoliolast weekDEFENSEPentagon's $80M Drone Defense Contract Points to the Counter-UAS Names Worth Watching4 weeks agoDEFENSEPentagon Awards Space-Based Target Tracking Contractslast weekENERGYNew Jersey's Nuclear Energy Law Opens a Real Revenue Path for Small Reactor Developers4 weeks agoENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakeslast weekDEFENSEU.S.-Iran Conflict Escalation Stalls Hormuz Shipping — Defense Contractors and Oil Majors Are the Immediate Read4 weeks agoWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employerslast weekWHITE HOUSETrump's Critical Minerals Order Cuts China Out of the Defense Supply Chain — and Sends Money to U.S. Miners4 weeks agoTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backinglast weekTECHBosch's $225M CHIPS Act Award for Roseville Chips Away at U.S. Dependence on Asian Auto Semiconductors4 weeks agoTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payoutlast weekCRYPTOWhite House Concedes Ethics Provision in Crypto Bill — Clearing the Last Roadblock for Stablecoin Legislation4 weeks agoHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanomalast weekENERGYTrump's Saudi Nuclear Pact Without Enrichment Safeguards Heads to Congress — U.S. Uranium and Nuclear Services Names Are the Play4 weeks agoHEALTHCARE & FDAFTC Sues Hims & Hers Over Privacy and Billing Practiceslast weekHEALTHCARE & FDACMS Freezes $1 Billion in Medicaid Payments to California and Minnesota — Managed Care Insurers Face Revenue Gaps4 weeks agoMARKETSFTC Threatens Booking Holdings Over Priceline Practiceslast weekTRADE & TARIFFSTrump's 50% Canada Tariff Threat Keeps U.S. Aluminum Tight — Domestic Producers Win, Manufacturers Pay3 weeks agoDEFENSERising Defense Spending Lifts Northrop Grumman Outlooklast weekDEFENSEHouse Passes $1.15T Defense Bill — Missile Defense, Shipbuilding, and Next-Gen Air Get the Money3 weeks agoTRADE & TARIFFSTrump Administration Hits $100B Tariff Refund Milestonelast weekENERGYNRC Approves Holtec's Upgraded Spent Fuel Storage System — A Quiet Win for Nuclear's Capacity Expansion3 weeks agoHEALTHCARE & FDACMS Raises IRF Payments for 2027—Rehab Hospitals Get Relieflast weekCRYPTOThe Senate's Landmark Crypto Bill Creates Winners Inside the ETF and Exchange Stack3 weeks agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressurelast weekENERGYTrump Signs the Saudi Nuclear Deal — and U.S. Uranium and Reactor Companies Are the Quiet Winners3 weeks agoHEALTHCARE & FDAHHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Winlast weekDEFENSEThe U.S.-Iran War Is Costing $37.5B and Counting — Here's Where That Money Goes3 weeks agoTRADE & TARIFFSAmazon Pockets $600M Tariff Refund—Retail Rivals Face Margin Squeezelast weekDEFENSEOracle Lands a $7B Pentagon Software Contract — and the Market Should Take It Seriously3 weeks agoENERGYMichigan Court Vacates Line 5 Permit—Enbridge Faces Shutdown Risklast weekWHITE HOUSETrump's Critical Minerals Order Cuts China Out of the Military Supply Chain — These Miners Fill the Gap3 weeks agoHEALTHCARE & FDAHumana Exits MA Markets—600K Members Face Plan Disruption2 weeks agoTRADE & TARIFFSTariffs on Indian Pharma Are Coming — and U.S. Generic Drug Buyers Will Pay the Bill3 weeks agoWHITE HOUSETrump Blocks Critical Minerals Exports—U.S. Miners Get Protected Market2 weeks agoHEALTHCARE & FDACMS's Star Ratings Overhaul Rescues the Biggest Medicare Advantage Insurers — For Now3 weeks agoDEFENSEHouse Passes $95B Iran War Package—Defense Contractors Lock in Revenue2 weeks agoMARKETSChina's $765M Antitrust Fine on Trip.com Is a Warning Shot for U.S.-Listed Chinese Consumer Stocks3 weeks agoHEALTHCARE & FDAFDA Revokes Petroleum-Based Food Dyes—Natural Color Makers Win2 weeks agoDEFENSEPentagon's $7B Oracle Software Deal Is One of the Cleanest Defense-Tech Wins in Years3 weeks agoTECHCommerce Awards $874M in Semiconductor R&D LOIs—Chip Makers Get Federal Backing2 weeks agoDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Direct Win for Oracle, Pressure on Smaller Defense IT Rivals3 weeks agoTRADE & TARIFFSAmazon Gets $600M Tariff Refund—Retailers Lift Guidance on Windfall2 weeks agoTECHFCC Tightens Submarine Cable Licensing Rules—Tech Giants Face New Compliance Costs, Telecom Carriers Gain Regulatory Clarity3 weeks agoSEARCH DEMANDData Center Power Exchange2 weeks agoHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—UnitedHealth, Humana, and Anthem Positioned to Gain from Simplified Metrics3 weeks agoSEARCH DEMANDCasgevy List Price: $2.2 Million2 weeks agoDEFENSEHouse Passes $1.15 Trillion Defense Bill—Lockheed, Raytheon, and General Dynamics Positioned for Record Spending3 weeks agoENERGYPHMSA Updates Pipeline Safety Standards—Compliance Costs Hit Operators, Benefit Inspectors2 weeks agoDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Largest Defense IT Overhaul in Years3 weeks agoMARKETSSEC Explores 23-Hour Stock Trading—Market Makers and Tech Platforms Get New Revenue2 weeks agoDEFENSERocket Lab Wins $266M Space Force Contract—Suborbital Launch Capability Becomes Defense Asset3 weeks agoDEFENSEHouse Passes $1.15T Defense Bill—Lockheed, Raytheon, General Dynamics Lock in Revenue2 weeks agoHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—Big Insurers Win, Quality Metrics Tighten3 weeks agoDEFENSEPentagon Awards Largest F-35 Spare Parts Contract—Lockheed Locks in Sustainment Revenue2 weeks agoDEFENSERocket Lab Wins $266M Space Force Missile Defense Contract—Suborbital Launch Niche Gets Federal Validation3 weeks agoHEALTHCARE & FDACMS Stars Redo Lifts Medicare Advantage Insurers—Rating System Overhaul Favors UnitedHealth, Humana, Anthem3 weeks agoDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Cloud Incumbents Face Pressure, Oracle Locks in Defense Revenue3 weeks agoCRYPTOSEC Settles Coinbase FOIA Suit Over Missing Gensler Texts—Crypto Compliance Pressure Eases, Coinbase Stock Gains Clarity3 weeks ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare

Orphan Drug Exclusivity Is Expiring Faster Than Investors Think: The Vertex-Biogen Patent-Cliff Scorecard

Two biotechs are racing the same clock on exclusivity — one built a legal and clinical bridge to the next franchise, the other is still patching the hole with a follow-on drug nobody asked for.

Image: Money Racket
By at Money Racket · Apr 11, 2026

The mechanism: Orphan drug exclusivity (seven years) and biologic exclusivity (12 years) are legal cliffs, not patent thickets you can litigate around forever. When they expire, the FDA can approve a competing product on safety and efficacy alone — no patent fight required. Biogen learned this the hard way when a federal judge invalidated its core Tecfidera patents in 2020 and Mylan launched a generic mid-quarter, vaporizing roughly a third of that quarter's revenue overnight. That precedent matters now because Biogen's second-largest franchise, Tysabri, lost its patent shield when the FDA approved Sandoz's natalizumab biosimilar Tyruko in August 2023 — and Sandoz finally launched it commercially in the U.S. in November 2025. Vertex is running the opposite playbook: it got FDA approval for Alyftrek in December 2024, a next-generation CFTR modulator clinically superior enough to reset the exclusivity clock and pull patients off Trikafta before generics ever get the chance.

Orphan exclusivity doesn't expire with a bang — it expires with an FDA approval letter for someone else's drug.

Who cashes in:

  • VRTX — Alyftrek is a defensive masterstroke: it converts Trikafta's expiring exclusivity into a fresh, patent-protected franchise built on the same CF patient base, while Casgevy (with partner CRISPR Therapeutics) is projected to nearly triple 2026 revenue as sickle-cell and beta-thalassemia patient starts scale, and Journavx gives Vertex a genuine non-CF, non-orphan growth leg.
  • NTLA — Intellia's lonvo-z, a one-time in vivo CRISPR treatment for hereditary angioedema, completed rolling BLA submission in 2026 with a targeted first-half-2027 launch; a first-in-category approval creates new orphan exclusivity from scratch rather than defending an old one, the model Vertex is proving works.
  • REGN — Regeneron's biologics franchise (Eylea HD, Dupixent) shows how patent-cliff-tested companies reload with label expansions and reformulations rather than relying on a single exclusivity period.

Who is exposed:

  • BIIB — Tysabri now has an FDA-approved, commercially launched biosimilar competitor, and Biogen's prior playbook (Vumerity as the "next-gen" successor to Tecfidera) generated a fraction of the revenue it needed to replace; Spinraza's U.S. orphan exclusivity has already lapsed, leaving Biogen dependent on Leqembi's slow Alzheimer's ramp to backfill two aging franchises at once.
  • GILD — HIV franchise biologic exclusivities age out on a rolling basis against a crowded generic and biosimilar bench, a structural tax on cash flow that management has to keep out-innovating.

The play: Score biotech patent cliffs by asking one question — did the company get a clinically superior successor approved before the exclusivity clock hit zero, or is it defending with a patent lawsuit? Vertex answered yes with Alyftrek; Biogen answered no with Tecfidera and is now replaying that same test with Tysabri. Watch FDA orphan drug designation and biologics license approval dockets for the tell before earnings do.

What to watch: FDA drug approval database entries for label-expansion or "clinically superior" successor filings ahead of known ODE/BLA exclusivity expiration dates.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://moneyracket.com/article/orphan-drug-exclusivity-cliff-vertex-biogen-scorecard/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →